Accordingly, everolimus has been FDA-approved as monotherapy in neuroendocrine tumor (NET) patients, TSC-associated SEGA patients, renal TSC-associated angiomyolipoma adult patients, and advanced-stage renal cell carcinoma (RCC) patients, as well as in combination with lenvatinib in advanced-stage RCC patients who have received a prior antiangiogenic therapy, and in combination with exemestane in postmenopausal HR + /HER2­ breast cancer patients with recurrence or progression following prior therapy with letrozole or anastrozole (Supplementary information 2) (Supplementary figure 1). This evidence concerns the gene ERBB2 and renal cell carcinoma.